-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II

Program: Oral and Poster Abstracts
Type: Poster
Hematology Disease Topics & Pathways:
Adult, apoptosis, Biological, multiple myeloma, survivorship, viral, Diseases, iPSCs, Lymphoma (any), Non-Biological, smoldering myeloma, cell regulation, Combinations, Elderly, Therapies, cellular interactions, chemotherapy, Biological Processes, enzyme inhibitors, cell expansion, immune cells, Technology and Procedures, Cell Lineage, cytogenetics, epigenetics, immunotherapy, Infectious Diseases, Plasma Cell Disorders, Lymphoid Malignancies, Study Population, Clinically relevant, genetic profiling, genomics, Myeloid Malignancies, Quality Improvement , flow cytometry, immune mechanism, NGS, metabolomics, microenvironment, molecular interactions, RNA sequencing, pathogenesis, pathways, proteomics
Sunday, December 6, 2020: 7:00 AM-3:30 PM

Yan Song, PhD1*, Ting DU, PhD2*, Arghya Ray, PhD2, Krishan Chauhan3*, Mehmet K. Samur, PhD4, Dharminder Chauhan, PhD2 and Kenneth Anderson, MD5

1Dana-Farber Cancer Institute, Harvard Medical School, Brookline, MA
2Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
3Department of Biomedical Engineering, Wentworth Institute of Technology, Boston, MA
4The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
5Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Ryosuke Shirasaki, MD, PhD1,2*, Sondra L. Downey-Kopyscinski, PhD1,2*, Ricardo De Matos Simoes, PhD1,2*, Olga Dashevsky1,2*, Sara Gandolfi, MD1,2*, Megan Bariteau, BSc1,2*, Aviad Tsherniak, PhD2*, Francisca Vazquez, Phd2*, Maria Themeli, MD, PhD3*, Jonathan D. Licht, MD4, Larry H. Boise, PhD5, Richard W.J. Groen, PhD3 and Constantine S. Mitsiades, MD, PhD2,6

1Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
2Broad Institute of MIT and Harvard, Cambridge, MA
3University Medical Center Utrecht, Amsterdam, Netherlands
4Department of Medicine, University of Florida, Gainesville, FL
5Emory University, Atlanta, GA
6Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Brookline, MA

Linda B Baughn, PhD1, Erik Jessen, PhD2*, Matthew Smith3*, Neeraj Sharma, PhD4*, Joselle Cook, MBBS4, Surendra Dasari, PhD2*, Kathryn E. Pearce, MS5*, Nathalie Meurice, PhD6*, Michael A. Linden, MD, PhD7, A. Keith Stewart, MB, ChB6,8,9, P. Leif Bergsagel, MD9, Brian G. Van Ness, PhD10 and Shaji K. Kumar, MD11

1Division of Laboratory Genetics, Mayo Clinic, Rochester, MN
2Department of Health Sciences Research, Mayo Clinic, Rochester, MN
3Mayo Clinic, Rochester
4Mayo Clinic, Rochester, MN
5Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
6Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ
7Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN
8Center for Individualized Medicine, Mayo Clinic, Rochester, MN
9Division of Hematology, Mayo Clinic, Scottsdale, AZ
10Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN
11Mayo Clinic Rochester, Division of Hematology, Rochester, MN

Cristina Panaroni, PhD1, Keertik Fulzele, PhD2*, Tomoaki Mori3*, Chukwuamaka Onyewadume3* and Noopur S. Raje, MD3*

1Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Cambridge, MA
2Forma Therapeutics, Inc., Watertown, MA
3Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, MA

Joaquin Martinez Lopez1*, Rafael Alonso Fernández2*, Sandy W. Wong, MD3, Rafael Rios, MD, PhD4*, Nina Shah, MD5, Maria Teresa Cedena Romero, MD, PhD6,7*, Yanira Ruiz-Heredia8*, Jose M. Sanchez, MD9*, Santiago Barrio Garcia, PhD10*, Thomas Martin III, MD11 and Jeffrey L. Wolf, MD11

1Department of Medicine, Division of Hematology-Oncology, University of Califarnia San Francisco, San Francisco
2Translational Hematology Group, Hospital 12 de Octubre-CNIO, Madrid, Spain
3Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA
4Servicio de Hematología y Hemoterapia, Hospital Universitario Virgen de las Nieves, Granada, Spain
5Associate Professor of Medicine, University of California San Francisco, San Francisco, CA
6Hospital 12 de Octubre, Madrid, Spain
7Department of Hematology, Hospital Universitario 12 de Octubre, CNIO, Madrid, Spain
8Hematology, Hospital Universitario 12 de Octubre, CNIO, Complutense, Madrid, Spain
9Hospital 12 de Octubre, Madrid, ESP
10Hematology, Hospital 12 de Octubre. CNIO, Madrid, Spain
11University of California, San Francisco, San Francisco, CA

Arghya Ray, PhD1, Ting DU, PhD1*, Yan Song, PhD2*, Sara J Buhrlage, PhD3*, Dharminder Chauhan, PhD1 and Kenneth Anderson, MD4

1Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
2Dana-Farber Cancer Institute, Harvard Medical School, Brookline, MA
3Biological Chemistry & Molecular Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
4The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Yuting Yan1*, Xiaoqi Qin2,3*, Lanting Liu4*, Shuhui Deng, MD1*, Jiahui Liu1*, Huishou Fan1*, Weiwei Sui, MD5*, Fu Mingwei, MD5*, Xue-Han Mao, MD6*, Zhen Yu, MD7*, Dehui Zou, MD1*, Lugui Qiu, MD1 and Gang An, MD, PhD1*

1National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China
3State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science, Tianjin, China
4Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical S, Tianjin, China
5State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin City, China
6Institute of Hematology & Blood Diseases Hospital, TIANJIN, China
7State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Urvi A Shah, MD1, Sæmundur Rögnvaldsson, BS2*, Andriy Derkach, PhD3*, Magnus Björkholm, MD, PhD4, Ingemar Turesson, MD, PhD5, Yael David, PhD6*, Malin Hultcrantz, MD, PhD1, Carlyn Tan, MD1, Hani Hassoun, MD1, Neha Korde, MD1, Alexander M. Lesokhin, MD1, Sham Mailankody, MBBS7, Sigurður Yngvi Kristinsson, MD, PhD8,9 and Ola Landgren, MD, PhD1

1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
2Faculty of Medicine, University of Iceland, Reykjavík, Iceland
3Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY
4Department of Medicine, Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden
5Department of Hematology, Skane University Hospital, Malmö, Sweden
6Memorial Sloan Kettering Cancer Center, New York, NY
7Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, New York, NY
8Department of Medicine, Karolinska University Hospital and Institutet, Stockholm, Sweden
9Faculty of Medicine, University of Iceland, Reykjavik, Iceland

Christopher T Su, MD1, Liying Chen, MS2*, Jason Chen, MD1, Brian Parkin, MD3, Avery Polk1*, Malathi Kandarpa, PhD1*, Craig E. Cole, MD4, Erica Campagnaro, MD1*, Josh Vo, PhD5*, Dan Robinson, PhD6*, Yi-Mi Wu, PhD6*, Moshe Talpaz, MD1, Jennifer Yesil, MSc7*, Daniel Auclair7, P. Leif Bergsagel, MD8, Arul Chinnaiyan, MD PhD6*, Veerabhadran Baladandayuthapani, PhD2* and J Christine Ye, MD, MSc1

1University of Michigan Medical Center, Ann Arbor, MI
2Department of Biostatistics, University of Michigan, Ann Arbor, MI
3VA Ann Arbor Healthcare System, Ann Arbor, MI
4Division of Hematology Oncology, Michigan State University, Lansing, MI
5Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI
6Department of Pathology, University of Michigan, Ann Arbor, MI
7Multiple Myeloma Research Foundation (MMRF), Norwalk, CT
8Division of Hematology, Mayo Clinic, Scottsdale, AZ

Yan Xie1*, Chengcheng FU, MD, PhD1*, Lingzhi Yan, MD, PhD1*, Song Jin, MD1*, Jingjing Shang, MD1*, Xiaolan Shi, MD, PhD1*, Jinlan Pan, MD1*, Yan Yin, MS2*, Tingting Mao, MS2*, Jing Deng, PhD2, Douglas D. Fang, MD, PhD2*, Dajun Yang, MD, PhD2*, Yifan Zhai, MD, PhD2*, Shuang Yan, MD1*, Yingying Zhai, MD1*, Ying Yao, MD1*, Panfeng Wang, MD1*, Jing Wang, MD1* and Depei Wu, MD, PhD1

1The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases (Suzhou), Jiangsu Institute of Hematology, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
2Ascentage Pharma (SuZhou) Co., Ltd, Suzhou, China

Chenxing Du, MD1*, Xue-Han Mao, MD2*, Jiahui Liu3*, Huishou Fan3*, Weiwei Sui, MD2*, Shuhui Deng, MD3*, Shuhua Yi, MD4*, Wenyang Huang3*, Yan Xu2*, Chengwen Li4*, Jiawei Zhao4*, Dehui Zou, MD4*, Yaozhong Zhao4*, Jianxiang Wang, MD5, Lugui Qiu, MD3 and Gang An, MD, PhD2*

1National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin City, China
2State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin City, China
3National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, TIANJIN, China
5State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Patrick Mellors1, Surendra Dasari, PhD2*, Mindy Kohlhagen3*, Bonnie Kaye Arendt3*, Morie Gertz4, Shaji K. Kumar, MD4, Francis K. Buadi, MB, CHB4*, Maria Alice V. Willrich, PhD3*, John A. Lust, MD, PhD5, Prashant Kapoor, MD4, Martha Q. Lacy, MD4, David Dingli, MD, PhD4, Yi L. Hwa, NP5, Amie Fonder, PA-C, MS5*, Miriam A. Hobbs, APRN, CNP, DNP5*, Suzanne R. Hayman, MD5, Taxiarchis Kourelis, MD4, Rahma M Warsame, MD6, Eli Muchtar, MD4*, Nelson Leung, MD5, Ronald S. Go, MD7, Yi Lin, MD, PhD5, Wilson I Gonsalves, MD4, Mustaqeem Siddiqui, MD5*, Robert A. Kyle, MD4, S. Vincent Rajkumar, MD4, David L. Murray, MD, PhD3* and Angela Dispenzieri, MD5*

1Department of Internal Medicine, Mayo Clinic, Rochester, MN
2Department of Health Sciences Research, Mayo Clinic, Rochester, MN
3Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
4Mayo Clinic Rochester, Division of Hematology, Rochester, MN
5Division of Hematology, Mayo Clinic, Rochester, MN
6Mayo Clinic, Rochester, MN
7Mayo Clinic Rochester, Division of Hematology, Onalaska, WI

Federica Costa1*, Rosanna Vescovini, PhD1*, Laura Notarfranchi1*, Paola Storti, PhD1*, Valentina Marchica, MS1*, Anna Benedetta Dalla Palma, MD1,2*, Cristina Manferdini, BS3*, Denise Toscani, PhD1*, Rosalba Eufemiese, MS1*, Jessica Burroughs, PhD1*, Gina Lisignoli, PhD4* and Nicola Giuliani1,2

1Department of Medicine and Surgery, University of Parma, Parma, Italy
2Hematology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
3Laboratory of Immunorheumatology and Tissue Regeneration, Istituto Ortopedico Rizzoli, Bologna, Italy
4Laboratory Immunorheumatology and Tissue Regeneration, Istituto Ortopedico Rizzoli, Bologna, Italy

Karen Sweiss, PharmD1, Gregory Sampang Calip, PharmD, MPH, PhD2*, Damiano Rondelli, MD3 and Pritesh Patel, MB, ChB3

1Department of Pharmacy Practice, University of Illinois, Hinsdale, IL
2Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago, Chicago, IL
3Division of Hematology/Oncology, University of Illinois, Chicago, IL

Subodh Kumar, PhD1,2*, Srikanth Talluri, PhD2,3*, Jiangning Zhao, PhD, MD3*, Chengcheng Liao, PhD, MD2,3*, Lakshmi B. Potluri, MBBS2,3*, Leutz Buon1*, Shidai Mu4*, Jialan Shi, MD, PhD2,3, Mychell Neptune-Buon2,4*, Chandraditya Chakraborty, Ph D3*, Yu-Tzu Tai, PhD3, Mehmet K. Samur, PhD3, Mariateresa Fulciniti, PhD3, Rao Prabhala2,3, Masood A. Shammas, PhD2,3* and Nikhil C. Munshi, MD2,3,5

1Dana Farber Cancer Institute, Boston, MA
2VA Boston Healthcare System, Boston, MA
3Dana-Farber Cancer Institute, Boston, MA
4Dana-Farber cancer institute, Boston, MA
5Harvard Medical School, Boston, MA

Alissa Visram, MD1*, Eli Muchtar, MD2, S. Vincent Rajkumar, MD3, Celine M. Vachon, PhD4, Angela Dispenzieri, MD5, Prashant Kapoor, MD3, Martha Q. Lacy, MD3, Francis K. Buadi, MB, CHB3*, Suzanne R. Hayman, MD1, Morie Gertz3, Robert A. Kyle, MD3 and Shaji K. Kumar, MD1

1Division of Hematology, Mayo Clinic, Rochester, MN
2Mayo Clinic Rochester, Division of Hematology, Saint Paul, MN
3Mayo Clinic Rochester, Division of Hematology, Rochester, MN
4Division of Epidemiology, Mayo Clinic, Rochester, MN
5Mayo Clinic, Rochester, MN

Ignacio Isola, MD1*, David Moreno, MD1*, Esther Moga, MD, PhD2*, Mari-Pau Mena, PhD1*, Natalia Tovar1*, Luis Gerardo Rodríguez-Lobato, MD, PhD1*, M. Teresa Cibeira, MD, PhD1*, Laura Rosinol, MD, PhD1*, Joan Bladé, MD, PhD1* and Carlos Fernandez de Larrea, MD, PhD1

1Amyloidosis and Myeloma Unit. Department of Hematology. Hospital Clínic de Barcelona. IDIBAPS., Barcelona, Spain
2Department of Immunology. Hospital de la Santa Creu I Sant Pau, Barcelona, Spain

Ryosuke Shirasaki, MD, PhD1*, Ricardo De Matos Simoes, PhD1,2*, Shizuka Yamano1,2*, Sondra L. Downey-Kopyscinski, PhD1,2*, Brian Glassner, PhD1,2*, Huihui Tang, PhD1,2*, Vikas Gupta, MD, PhD3*, Aviad Tsherniak, PhD2*, Francisca Vazquez, Phd2*, Jonathan D. Licht, MD4, Larry H. Boise, PhD3 and Constantine S. Mitsiades, MD, PhD2,5

1Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
2Broad Institute of MIT and Harvard, Cambridge, MA
3Emory University, Atlanta, GA
4Department of Medicine, University of Florida, Gainesville, FL
5Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Brookline, MA

Luciano J. Costa, MD, PhD1, Nicholas Burwick, MD2, Andrzej Jakubowiak, MD, PhD3, Jonathan L. Kaufman, MD4, Fernando Cabanillas, MD5, Monique Dail, PhD6*, Sudeep Karve7*, Abdullah A. Masud, PhD8*, Xiaoqing Yang, PhD7*, Orlando F. Bueno7, Sarah Mudd, PhD8*, Jeremy A. Ross7* and Faith E. Davies9

1Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL
2Department of Hospital and Specialty Medicine, Veterans Affairs Puget Sound Health Care System, Seattle, WA
3University of Chicago Medicine, Chicago, IL
4Winship Cancer Institute of Emory University, Atlanta, GA
5Auxilio Mutuo Cancer Center, San Juan, PR
6Genentech Inc., South San Francisco, CA
7AbbVie, Inc., North Chicago, IL
8AbbVie Inc., North Chicago, IL
9Perlmutter Cancer Center, NYU Langone Health, New York, NY

Ana Jimenez-Ubieto1*, Bruno Paiva, PhD2*, Joaquin Martinez Lopez3,4*, María Teresa Cedena, MD5*, Noemi Puig, MD, PhD6*, Albert Oriol, MD7*, Maria Jesús Blanchard, MD8*, Rafael Rios, MD, PhD9*, Lucia Lopez-Anglada, PhD10*, Jesús Martín11*, Rafael Martínez12*, Anna Sureda Balari, MD, PhD13*, Miguel Hernández14*, Javier de la Rubia15,16*, Isabel Krsnik, MD, PhD17*, Valentin Cabañas, MD18*, Luis Palomera, MD, PhD19*, Joan Bargay, MD20*, Jose Maria Moraleda, MD, PhD21*, Laura Rosinol, MD, PhD22*, María-Victoria Mateos, MD, PhD23, Jesus F. San-Miguel, MD, PhD24, Joan Bladé, MD, PhD25 and Juan-José Lahuerta, MD, PhD26*

1Hematology, Hospital 12 de Octubre. Madrid, Madrid, Spain
2Clinica Universidad De Navarra, Pamplona, Navarra, Spain
3Hospital Universitario 12 de Octubre, Madrid, Spain
4Hematology Department Hospital 12 de Octubre, Complutense University, H12O-CNIO Clinical research unit, CIBERONC, Madrid, Spain
5Hematology Department, Hospital Universitario 12 de Octubre,, Madrid, Spain
6Hospital Universitario de Salamanca Hematología. Instituto de investigación biomédica de Salamanca (IBSAL), Salamanca, Spain
7Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain
8Hematology and Hemotherapy Department, Hospital Universitario Ramón y Cajal, Madrid, Spain
9Hospital Universitario Virgen de las Nieves de Granada, Granada, Spain
10Hospital 12 de Octubre, Madrid, Spain
11Hospital Virgen del Rocío, Sevilla, Spain
12Hospital Clínico San Carlos, Madrid, Spain
13Hematology Department, Institut Català d'Oncologia Hospitalet, Barcelona, Spain
14Hospital Universitario De Canaria, La Laguna, ESP
15Hematology Department, Universidad Católica de Valencia Hospital Dr. Peset, Valencia, Spain
16Hematology Department, Internal Medicine, School of Medicine and Dentistry, Catholic University of Valencia, Valencia, Spain
17Hospital Universitario Puerta de Hierro, Madrid, Spain
18Hospital Virgen de la Arrixaca de Murcia, Murcia, Spain
19Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
20Department of Hematology, Son Llatzer University Hospital/ IdISBa, Palma de Mallorca, Spain
21Hematopoietic Transplant and Cellular Therapy Unit, Instituto Murciano de Investigación Biosanitaria IMIB-Arrixaca, Virgen de la Arrixaca University Hospital, University of Murcia, Murcia, Spain, Murcia, Spain
22Servicio de Onco-Hematología, Hospital Clínica de Barcelona, Barcelona, Spain
23Institute of Cancer Molecular and Cellular Biology, University Hospital of Salamanca, Salamanca, Spain
24Clinica Universidad de Navarra, Pamplona, Spain
25Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
26Hospital 12 de Octubre, CIBERONC, Madrid, Spain

Maria Gavriatopoulou1*, Andriani Boultadaki2*, Vassilis Koutoulidis, MD2*, Ioannis Ntanasis-Stathopoulos, MD1*, Charis Bourgioti2*, Panagiotis Malandrakis, MD1*, Despina Fotiou, BMBS, MA1*, Magdalini Migkou3*, Nikolaos Kanellias, MD1*, Evangelos Eleutherakis-Papaiakovou, MD1*, Efstathios Kastritis, MD4*, Evangelos Terpos, MD, PhD1, Meletios A. Dimopoulos, MD1 and Lia A. Moulopoulos, MD2*

1Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
2First Department of Radiology, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
3National and Kapodistrian University of Athens, Athens, Greece
4National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

Carlotta Welters1*, Meng-Tung Hsu2*, Christian Alexander Stein1*, Livius Penter1,3*, María Fernanda Lammoglia Cobo1*, Kerstin Dietze1*, Eric Blanc4*, Dieter Beule4*, Lars Bullinger, MD1, Julian Strobel5*, Holger Hackstein5*, Armin Gerbitz, MD PhD6*, Klaus Dornmair7*, Thomas Blankenstein2,8,9,10* and Leo Hansmann1,9,10*

1Department of Hematology, Oncology, and Tumor Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
2Molecular Immunology and Gene Therapy, Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston
4Core Unit Bioinformatics, Berlin Institute of Health, Berlin, Germany
5Transfusion Medicine and Haemostaseology, Friedrich-Alexander-University Erlangen, Erlangen, Germany
6Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada
7Institute of Clinical Neuroimmunology, Biomedical Center and Hospital of the LMU, Munich, Germany
8Institute of Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
9Berlin Institute of Health, Berlin, Germany
10Partner Site Berlin, German Cancer Consortium (DKTK), Berlin, Germany

Adam S Sperling, MD, PhD1*, Rebecca Georgakopoulou, MSc2*, Mehmet Kemal Samur, PhD1*, Christine Ivy Liacos, MSc2*, Brittany E Sandoval, MSc1*, Flora Zagouri, MD2*, Maria Gavriatopoulou2*, Evangelos Eleutherakis-Papaiakovou, MD2*, Magdalini Migkou3*, Nikolaos Kanellias, MD2*, Despina Fotiou, BMBS, MA2*, Ioannis Ntanasis-Stathopoulos, MD2*, Evangelos Terpos, MD, PhD2, Efstathios Kastritis, MD2*, Nikhil C. Munshi, MD1 and Meletios A Dimopoulos4

1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
2Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
3National and Kapodistrian University of Athens, Athens, Greece
4Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece

Eileen M Boyle, MD, MSc1,2, Louis Williams, MD, MBA2, Patrick Blaney3*, Cody Ashby, PhD4*, Michael A Bauer, PhD5, Brian A Walker, PhD6,7, Jinyoung Choi, PhD8*, Jessica Caro, MD9, Beatrice Razzo, MD10, Arnaldo A. Arbini, MD11*, David Kaminetzky, MD12*, Marc Braunstein, MD, PhD13, Francesco Maura, MD14, Yubao Wang, PhD15*, Ola Landgren, MD, PhD14, James Stoeckle, MD16*, Kylee H Maclachlan, MBChB, PhD14*, Rachel Litke17*, Faith E. Davies2 and Gareth Morgan, MD, PhD9

1Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Health, New York, NY
2Laura & Isaac Perlmutter Cancer Center, NEW YORK UNIVERSITY SCHOOL OF MEDICINE, New York, NY
3Perlmutter Cancer Center, NEW YORK UNIVERISITY, New York, NY
4Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR
5Department of Biomedical Informatics, University of Arkansas For Medical Sciences, Little Rock, AR
6Division of Hematology Oncology, Indiana University, Indianapolis, IN
7Indiana University, Division of Hematology Oncology, Indianapolis, IN
8Myeloma Research Program, Laura and Isaar Perlmutter Cancer Center, NEW YORK UNIVERSITY, New-York, NY
9Perlmutter Cancer Center, New York University Langone Health, New York, NY
10Myeloma Research Program, Laura and Isaac Perlmutter Cancer Center, NEW YORK UNIVERSITY, New-York, NY
11NYU Langone Medical Center, New York, NY
12NYU Langone Health, New York, NY
13Division of Oncology-Hematology, NYU Long Island School of Medicine, NYU Winthrop Hospital, NYU Langone Health, Great Neck, NY
14Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
15Perlmutter Cancer Center,, Myeloma Research Program, New York, NY
16Perlmutter Cancer Center, NYU Langone Medical Center, Myeloma Research Program, New York, NY
17Icahn School of Medicine at Mount Sinai, New York, NY

Hadiyah Y. Audil, MD1*, Joselle Cook, MBBS2, Patricia Greipp, DO3, Prashant Kapoor, MD4, Linda B Baughn, PhD3, Angela Dispenzieri, MD2, Morie A Gertz, MD2, Francis K. Buadi, MB, CHB2*, Martha Q. Lacy, MD2, David Dingli, MD, PhD4, Amie Fonder, PA-C, MS2*, Suzanne R. Hayman, MD2, Miriam A. Hobbs, APRN, CNP, DNP2*, Eli Muchtar, MD2*, Mustaqeem A. Siddiqui, MD, MBA2, Wilson I Gonsalves, MD4, Yi L. Hwa, NP2, Nelson Leung, MD2, Ronald S. Go, MD2, Yi Lin, MD, PhD2, Taxiarchis Kourelis, MD4, Rahma M Warsame, MD2,4, John A. Lust, MD, PhD2, Robert A. Kyle, MD5, Rhett P. Ketterling, MD3*, S. Vincent Rajkumar, MD2 and Shaji K. Kumar, MD2

1Division of Internal Medicine, Mayo Clinic, Rochester, MN
2Division of Hematology, Mayo Clinic, Rochester, MN
3Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
4Mayo Clinic, Rochester, MN
5Mayo Clinic Rochester, Division of Hematology, Rochester, MN

Laura Notarfranchi1*, Rosanna Vescovini, PhD1*, Roberta Segreto, MS2*, Sabrina Bonomini, MS2*, Paola Storti, PhD1*, Valentina Marchica, MS1*, Federica Costa1*, Gabriella Sammarelli, PhD2*, Giannalisa Todaro, PhD2*, Maria Teresa Catarozzo, MS1*, Dario De Giovanni, MD1*, Vincenza Fabiano, MD1*, Anna Benedetta Dalla Palma, MD1,2* and Nicola Giuliani1,2

1Department of Medicine and Surgery, University of Parma, Parma, Italy
2Hematology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy

Meera Mohan, MD1, Samantha Kendrick, PhD2*, Yadav Pandey, MD3*, Richa Parikh, MD4*, Phil Farmer4*, Mathew Kottarathara, MD4*, Shadiqul Hoque, MD4*, Angel Mitma, MD4*, Sharmilan Thanendrarajan, MD4, Carolina D. Schinke, MD4, Guido Tricot, MD, PhD4*, Maurizio Zangari, MD, FACP4 and Frits van Rhee, MD4

1Clinical Cancer Center, Division of Hematology Oncology, Medical College of Wisconsin, Milwaukee, WI
2Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR
3Department of Hematology Oncology, University of Arkansas for Medical Sciences, Little Rock, AR
4Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR

Xue-Han Mao, MD1*, Yan Xu, MD2,3*, Yuting Yan4*, Junling Zhuang, MD, PhD5*, Huishou Fan4*, Weiwei Sui4*, Jiahui Liu4*, Shuhui Deng, MD4*, Shuhua Yi, MD6*, Lugui Qiu, MD4 and Gang An7*

1Institute of Hematology & Blood Diseases Hospital, TIANJIN, China
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
3Institute of Hematology & Blood Diseases Hospital, Chinese Academic Medical Science & Peking Union Medical College, Tianjin, China
4National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5Peking Union Medical Colleague Hospital, Nashville, TN
6National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Duarte, CA
7lymphoma and myeloma center, National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Isabel Cuenca, MSc1*, Alejandro Medina, MD2*, Laura Rosinol, MD, PhD3*, Iria Vazquez, PhD, BSc4,5*, Ricardo Sanchez6*, Norma C. Gutierrez, MD, PhD7,8*, Yanira Ruiz-Heredia9*, Santiago Barrio6*, Albert Oriol, MD10*, Maria Luisa Martin-Ramos11*, Manuela Fernández-Guijarro11*, María Jesús Blanchard12*, Rafael Rios, MD, PhD13,14*, Anna Sureda Balari, MD, PhD15*, Miguel T Hernández16*, Javier de la Rubia17*, Gorka Alkorta18*, Xabier Agirre, PhD19*, Gonzalo R Ordóñez20*, Rafael Valdés-Mas21*, Maria-Victoria Mateos, MD, PhD22, Joan Blade Creixenti23, Juan Jose Lahuerta, MD, PhD24*, Jesus F. San-Miguel, MD, PhD25,26, Maria Jose Calasanz, PhD, BSc27*, Ramon Garcia-Sanz28 and Joaquin Martinez-Lopez, MD, PhD6*

1Hematology Department Hospital 12 de Octubre, Complutense University, H12O-CNIO Clinical research unit, Madrid, Spain
2Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain., Salamanca, Spain
3Hematology, Hospital Clinic i Provincial, Barcelona, Spain
4Navarra Institute for Health Research (IdiSNA), Pamplona, Spain; Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, CIMA LAB Diagnostics, University of Navarra, Hematological Diseases Laboratory, Pamplona, Spain
5Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain
6Hematology Department Hospital 12 de Octubre, Complutense University, H12O-CNIO Clinical research unit, CIBERONC, Madrid, Spain
7Servicio de Hematología, Hospital Universitario de Salamanca (HUSAL/IBSAL), and IBMCC (USAL-CSIC), Salamanca, Spain
8Departamento de Hematología, Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain
9Department of Translational Hematology, Research Institute Hospital 12 de Octubre (i+12) Hematological Tumors Clinical Research Unit H12O-CNIO, Madrid, Spain, Madrid, Spain
10Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain
11Hospital Universitario 12 de Octubre, Madrid, Spain
12Hospital Ramón y Cajal, Madrid, Spain
13Hospital Universitario Virgen de las Nieves de Granada, Granada, Spain
14Servicio de Hematología y Hemoterapia, Hospital Universitario Virgen de las Nieves, Granada, Spain
15ICO-Hospital Duran i Reynals, Hospitalet del Llobregat, Spain
16Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
17Hematology Service, University Hospital Doctor Preset, Valencia, Spain
18Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), Centro de Investigación Biomédica en Red de Cáncer (CIBER-ONC)., Pamplona, Spain
19Hematology-Oncology Program, Centro de Investigación Médica Aplicada (CIMA), IDISNA, Universidad de Navarra, Pamplona, Spain
20Disease Research And Medicine (DREAMgenics) S. L., Oviedo, Spain
21Dreamgenics, Oviedo, ESP
22University Hospital of Salamanca/IBSAL/Cancer Research Center- IBMCC (USAL-CSIC), Salamanca, Spain
23Hematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain
24Hospital Doce de Octubre, CIBERONC, Madrid, Spain
25Hematology Department, Clínica Universidad De Navarra, Pamplona, Spain
26Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), IDISNA, CIBERONC, Pamplona, Spain
27Centro de Investigación Médica Aplicada (CIMA), IDISNA, CIBERONC, Clínica Universidad de Navarra, Pamplona, Spain
28Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain

Yang Liang, MD1, Han-ying Huang2*, Yun Wang, MD, PhD2*, Weida Wang, MD, PhD2*, Jin-Yuan Li2* and Ling-ling Shu2*

1Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
2State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine; Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China

Jishi Wang, PhD1 and Jie Xiong, M.D.2*

1Department of Hematology, Affiliated Hospital, Guizhou Medical University, Guiyang, China., Chongqing, China
2Affiliated Hospital of Guizhou Medical University, Guiyang, China

Annita Ioanna Gkioka, MD1*, Aspasia Koudouna, MD1*, Vasiliki Bartzi, MD1*, Maria Dimou, MD, PhD1, Theodoros Iliakis, MD2*, Aikaterini Bitsani, MD1*, Vasileios Pardalis, MD2*, Panayiotis Panayiotidis, MD1 and Marie-Christine Kyrtsonis, MD1

1First Department of Propedeutic Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
21st Department of Propedeutic Medicine, Hematology Clinical trials Unit, Laikon General Hospital, Medical School , National and Kapodistrian University of Athens, Athens, Greece

David Zihala1,2*, Tereza Sevcikova1,2,3*, Michal Simicek1,2,3*, Tereza Popkova2*, Hana Plonkova2*, Lucie Broskevicova2*, Jan Vrana1,2*, Juli R. Bago1,2*, Roman Hajek1,2, Giovanni Stracquadanio4* and Tomas Jelinek1,2*

1Department of Clinical Studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
2Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic
3Department of Biology and Ecology, Faculty of Science, University of Ostrava, Ostrava, Czech Republic
4Institute of Quantitative Biology, Biochemistry, and Biotechnology, SynthSys, School of Biological Sciences, University of Edinburgh, Edinburgh, United Kingdom

Shaadi Mehr, PhD1*, Daniel Auclair1, Mark Hamilton, PhD1*, Leon Rozenblit2*, Hearn Jay Cho, MD, PhD3,4, Lijun Yao5*, Reyka G Jayasinghe, PhD5*, Manoj Bhasin, PhD6*, Steven E. Labkoff, MD1*, Taxiarchis Kourelis, MD7, Madhav V. Dhodapkar, MD8, Deon Doxie9*, Sacha Gnjatic10*, Cassandra Dewitt2* and Sergey Miron2*

1Multiple Myeloma Research Foundation, Norwalk, CT
2Prometheus, New Haven, CT
3The Multiple Myeloma Research Foundation, Mount Sinai School of Medicine, New York, NY
4MMRF; Icahn School of Medicine at Mount Sinai, Norwalk, CT
5Department of Medicine, Washington University School of Medicine, Saint Louis, MO
6Emory School of Medicine, Aflac Cancer and Blood Disorders Center, Atlanta, GA
7Mayo Clinic Rochester, Division of Hematology, Rochester, MN
8Emory University School of Medicine, Atlanta, GA
9Emory University, Atlanta, GA
10Mount Sinai School of Medicine, New York, NY

Misaki Sugai, BS1*, Naohiro Tsuyama, PhD1*, Yu Abe, PhD1*, Yusuke Azami, MD2*, Kenichi Kudo, PhD3*, Akinobu Ota, PhD4*, Sivasundaram Karnan, PhD5*, Moe Muramatsu, BS6*, Tomonari Shigemura, MD, PhD7*, Megumi Sasatani, PhD8*, Yuko Hashimoto, MD, PhD6*, Kenji Kamiya, MD, PhD8*, Ichiro Hanamura, MD, PhD9*, Takayuki Ikezoe, MD, PhD10, Masafumi Onodera, MD, PhD11* and Akira Sakai, MD, PhD1

1Dept. of Radiation Life Sciences, Fukushima Medical University School of Medicine, Fukushima, Japan
2Dept. of Medical Oncology, Fukushima Medical University School of Medicine, Fukushima, Japan
3Dept. of Radiation Life Sciences, Fukushima Med. Univ. School of Medicine, Fukushima, Japan
4Dept. of Hematology, Aichi Medical University School of Medice, Nagakute, Japan
5Dept. of Hematology, Aichi Med. Univ. School of Medicine, Nagakute, Japan
6Dept. of Diagnostic Pathology, Fukushima Medical University School of Medicine, Fukushima, Japan
7Dept. of Pediatrics, Shinshu University, Matsumoto, Japan
8Dept. of Experimental Oncology, RIRBM, Hiroshima University, Hiroshima, Japan
9Dept. of Hematology, Aichi Medical University School of Medicine, Nagakute, Japan
10Dept of. Hematology, Fukushima Medical University School of Medicine, Fukushima, Japan
11Dept. of Genetics, National Research Institute for Child Health and Development, Tokyo, Japan

*signifies non-member of ASH